Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $13.59, for a total value of $59,796.00. Following the completion of the transaction, the chief executive officer now directly owns 737,767 shares in the company, valued at $10,026,253.53. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Atara Biotherapeutics, Inc. (ATRA) traded up 4.04% on Monday, reaching $14.15. The company’s stock had a trading volume of 188,985 shares. Atara Biotherapeutics, Inc. has a 12 month low of $11.80 and a 12 month high of $23.00. The firm’s 50 day moving average is $15.39 and its 200-day moving average is $15.07. The firm’s market cap is $432.41 million.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities research analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.90) EPS for the current year.
Several research analysts have recently commented on the company. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a report on Friday, October 6th. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Canaccord Genuity reissued a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a report on Monday, September 11th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $24.40.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.